Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 4/20 | 0.71 |
| ▸ | FABP1 | P07148 | 4/20 | 0.71 |
| ▸ | PARP1 | P09874 | 1/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5944076 | 0.91 | PARP1 (0.74) | P2RY14FABP1PARP1HDAC8HDAC6 | |
| SCHEMBL5943868 | 0.87 | P2RY14 (0.77) | P2RY14FABP1PARP1PTPN1PKM | |
| SCHEMBL31018815 | 0.86 | FABP1 (0.67) | P2RY14FABP1HDAC2PTPN1PKM | |
| SCHEMBL2719018 | 0.86 | P2RY14 (0.89) | P2RY14FABP1PTPN1PKML3MBTL1 | |
| SCHEMBL5943876 | 0.85 | PARP1 (0.62) | P2RY14FABP1PARP1HDAC8HDAC6 | |
| SCHEMBL5031589 | 0.85 | FABP1 (0.73) | P2RY14FABP1PARP1PTPN1PKM | |
| SCHEMBL5944168 | 0.84 | P2RY14 (0.72) | P2RY14FABP1PARP1HDAC8HDAC6 | |
| SCHEMBL5943989 | 0.83 | HDAC6 (0.66) | P2RY14FABP1PARP1HDAC8HDAC6 | |
| SCHEMBL31018807 | 0.83 | FABP1 (0.79) | P2RY14FABP1PTPN1PKML3MBTL1 | |
| SCHEMBL16168063 | 0.83 | P2RY14 (0.66) | P2RY14FABP1PARP1PTPN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | claimed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | claimed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | P2RY14 4746/4885FABP1 1686/4885PARP1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.